Table 2.

Cox Proportional Hazard Analysis for the Primary Outcome

	Unadjusted model			Adjusted Model*
	HR	95% CI	P value	HR	95% CI	P value
Log‐transformed BNP	2.19	1.38–3.47	<0.001	2.12	1.31–3.43	0.002
Age, y	1.03	1.01–1.05	0.016
Male sex	1.33	0.79–2.22	0.280
LVEF, per 10%	0.81	0.68–0.96	0.015
Medical history
Atrial fibrillation	2.01	0.91–4.44	0.084
Diabetes	0.61	0.32–1.18	0.145
Hypertension	1.21	0.71–2.05	0.487
Pacemaker implantation	0.87	0.49–1.55	0.633
ICD/CRT‐D implantation	1.61	0.76–3.41	0.211
Gallium‐67 accumulation	1.40	0.74–2.65	0.306
PET accumulation	0.46	0.14–1.51	0.200
LGE on CMR	1.62	0.49–5.40	0.433
Manifestation at diagnosis
Atrioventricular block	0.76	0.46–1.27	0.291
Basal thinning of the IVS	1.38	0.82–2.31	0.221
Wall motion abnormality	1.15	0.69–1.91	0.585
VT/VF	3.28	1.91–5.63	<0.001	2.94	1.65–5.25	<0.001
eGFR, per 10 mL/min per 1.73 m2	0.84	0.76–0.94	0.002
Creatinine, mg/dL	1.38	1.07–1.70	0.011
ACEi/ARB at baseline	1.52	0.92–2.52	0.101
Beta blocker at baseline	1.35	0.80–2.29	0.267
Steroid use after diagnosis	0.43	0.26–0.84	0.012	0.49	0.25–0.98	0.044

ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, B‐type natriuretic peptide; CMR, cardiac magnetic resonance; CRT‐D, cardiac resynchronization therapy defibrillator; eGFR, estimated glomerular filtration rate; HR, hazard ratio; ICD, implantable cardioverter‐defibrillator; IVS, interventricular septum; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; PET, positron emission tomography; VF, ventricular fibrillation; and VT, ventricular tachycardia.

^*Adjusted model was determined using backward stepwise approach.